Pacira Biosciences, Stock Alpha and Beta Analysis
| PCRX Stock | USD 26.07 0.01 0.04% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Pacira BioSciences,. It also helps investors analyze the systematic and unsystematic risks associated with investing in Pacira BioSciences, over a specified time horizon. Remember, high Pacira BioSciences,'s alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Pacira BioSciences,'s market risk premium analysis include:
Beta 0.85 | Alpha (0.03) | Risk 2.18 | Sharpe Ratio 0.0544 | Expected Return 0.12 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Pacira BioSciences, Backtesting, Pacira BioSciences, Valuation, Pacira BioSciences, Correlation, Pacira BioSciences, Hype Analysis, Pacira BioSciences, Volatility, Pacira BioSciences, History and analyze Pacira BioSciences, Performance. Pacira BioSciences, Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Pacira BioSciences, market risk premium is the additional return an investor will receive from holding Pacira BioSciences, long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Pacira BioSciences,. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Pacira BioSciences,'s performance over market.| α | -0.03 | β | 0.85 |
Pacira BioSciences, expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Pacira BioSciences,'s Buy-and-hold return. Our buy-and-hold chart shows how Pacira BioSciences, performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Pacira BioSciences, Market Price Analysis
Market price analysis indicators help investors to evaluate how Pacira BioSciences, stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Pacira BioSciences, shares will generate the highest return on investment. By understating and applying Pacira BioSciences, stock market price indicators, traders can identify Pacira BioSciences, position entry and exit signals to maximize returns.
Pacira BioSciences, Return and Market Media
The median price of Pacira BioSciences, for the period between Thu, Oct 2, 2025 and Wed, Dec 31, 2025 is 23.81 with a coefficient of variation of 6.75. The daily time series for the period is distributed with a sample standard deviation of 1.61, arithmetic mean of 23.82, and mean deviation of 1.32. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Pacira BioSciences Given Sell Rating at Weiss Ratings - MarketBeat | 10/10/2025 |
2 | Is Pacira BioSciences Inc. stock poised for growth - July 2025 Earnings Daily Market Momentum Tracking - newser.com | 10/29/2025 |
3 | Disposition of 6690 shares by Shawn Cross of Pacira BioSciences, at 21.38 subject to Rule 16b-3 | 10/31/2025 |
4 | Disposition of 12060 shares by Shawn Cross of Pacira BioSciences, at 22.09 subject to Rule 16b-3 | 11/10/2025 |
5 | How Pacira BioSciences Inc. stock valuation compares with sector - Weekly Loss Report Reliable Price Breakout Alerts - newser.com | 11/12/2025 |
6 | Acquisition by Kronenfeld Mark A. of 5230 shares of Pacira BioSciences, subject to Rule 16b-3 | 11/21/2025 |
7 | Pacira BioSciences Files EXPAREL Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical | 11/26/2025 |
8 | Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 12/03/2025 |
9 | How Investors Are Reacting To Pacira BioSciences Spine Pain Trial Win And New FDA Clearance - simplywall.st | 12/04/2025 |
10 | Pacira BioSciences Valuation Check After New Iovera Clinical Data and Smart Tip FDA Clearance | 12/10/2025 |
11 | Pacira BioSciences stock earns technical rating upgrade - MSN | 12/16/2025 |
12 | Acquisition by Bigal Marcelo of 1512 shares of Pacira BioSciences, at 13.25 subject to Rule 16b-3 | 12/18/2025 |
13 | IBD Rating Upgrades Pacira BioSciences Flashes Improved Technical Strength - Investors Business Daily | 12/29/2025 |
About Pacira BioSciences, Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Pacira or other stocks. Alpha measures the amount that position in Pacira BioSciences, has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Dividend Yield | 0.001154 | 0.001442 | Price To Sales Ratio | 1.24 | 1.18 |
Pacira BioSciences, Upcoming Company Events
As portrayed in its financial statements, the presentation of Pacira BioSciences,'s financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pacira BioSciences,'s leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Pacira BioSciences,'s public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Pacira BioSciences,. Please utilize our Beneish M Score to check the likelihood of Pacira BioSciences,'s management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Pacira BioSciences,
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Pacira Stock Analysis
When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.